文献速递临床试验与 GCP

龙牡汤颗粒治疗特应性皮炎的疗效与安全性:单中心、双盲、随机、安慰剂对照试验的研究方案

The efficacy and safety of Longmu Tang granule for the treatment of atopic dermatitis: study protocol for a single-centred, double-blinded, randomised, placebo-controlled trial.
PubMed 文献 · Trials · 2022-05-09

本研究为单中心、双盲、随机、安慰剂对照试验,计划纳入60例特应性皮炎患者,按1:1随机分配接受龙牡汤颗粒或安慰剂颗粒治疗8周。主要结局采用特应性皮炎评分指数评估,次要结局采用儿童皮肤病生活质量指数和数字划消试验评估,机制证据为血清免疫球蛋白E、肿瘤坏死因子-α、白细胞介素-1和白细胞介素-6水平。

要点

  • 龙牡汤颗粒自2008年起经医生处方用于有效治疗特应性皮炎。
  • 试验计划纳入60例受试者,按1:1随机分配,治疗8周。
  • 主要结局为特应性皮炎评分指数,机制证据为血清炎症细胞因子水平。

核心结论

  • 该试验结果将提供龙牡汤颗粒治疗特应性皮炎疗效和安全性的证据,并证明其抗炎作用。

研究设计与样本

  • 单中心、双盲、随机、安慰剂对照临床试验,在中国中医科学院西苑医院开展。
  • 计划纳入60例受试者,按1:1随机分配接受龙牡汤颗粒或安慰剂颗粒,疗程8周。
  • 主要结局采用特应性皮炎评分指数评估;次要结局采用儿童皮肤病生活质量指数和数字划消试验评估。
  • 机制证据为血清免疫球蛋白E、肿瘤坏死因子-α、白细胞介素-1和白细胞介素-6水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic relapsing skin disease that has long-term physical and mental health impacts on children with this condition. Current treatments mainly include anti-inflammatory, antibacterial, and anti-allergic interventions, systemic therapy, and recently emerging target-focused agents. However, these treatments have limited effectiveness and unwanted side effects. The use of traditional Chinese medicine (TCM) in the treatment of AD has a long history, with promising efficacies, low toxicity, and improvements in the quality of life of patients with AD. Longmu Tang granule, a TCM, has been used to effectively treat AD since 2008 through doctors' prescriptions. To scientifically evaluate the clinical efficacy and safety of Longmu Tang granule, we proposed to launch a single-centred, double-blinded, randomised, placebo-controlled trial. METHODS: In this single-centred, double-blinded, randomised, placebo-controlled clinical trial conducted at Xiyuan Hospital of China Academy of Chinese Medical Sciences, a total of 60 participants will be randomly assigned (1:1) to receive the Longmu Tang granule or placebo granule for 8 weeks. The primary outcome will be evaluated using the index of Scoring Atopic Dermatitis. The secondary outcomes will be evaluated using the Children's Dermatology Life Quality Index and the number cancellation test. The mechanistic evidence will be the serum levels of inflammatory cytokines, including immunoglobulin E, tumour necrosis factor-α, interleukin-1, and interleukin-6. DISCUSSION: The results of this trial will provide evidence of the efficacy and safety of the Longmu Tang granule and prove its anti-inflammatory action in patients with AD. TRIAL REGISTRATION: Chinese Clinical Trial Registry Chictr.org ID: ChiCTR2100041591 . Registered on 1 January 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li YQ, Shen TT, Wang QY, et al. The efficacy and safety of Longmu Tang granule for the treatment of atopic dermatitis: study protocol for a single-centred, double-blinded, randomised, placebo-controlled trial. Trials. 2022. PMID: 35534883. doi:10.1186/s13063-022-06313-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。